Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia (XCL1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01380587|
Recruitment Status : Completed
First Posted : June 27, 2011
Last Update Posted : August 27, 2013
|Condition or disease|
|Acute Lymphoblastic Leukemia|
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
Acute Lymphoblastic Leukemia
We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
- Number of patients with poor prognosis and high levels of XCL1 [ Time Frame: 3 months ]Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
- Number of patients with poor prognosis and high levels of cytokines [ Time Frame: 3 months ]Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01380587
|Hospital Universitario Dr. Jose E. Gonzalez UANL|
|Monterrey, Nuevo Leon, Mexico, 64460|
|Principal Investigator:||Cesar H Gutierrez Aguirre, MD||Hospital Universitario Dr. Jose E. Gonzalez UANL|